The incidence rates of other thromboembolic events and for all-cause death were also low in this unselected patient population.
All patients were screened sequentially and documented in an anonymous log file independent of therapy.A total of 2709 patients (39.9%) had a treatment-emergent AE and 1200 (17.7%) had a treatment-emergent SAE.The studies will include real-world data about Xarelto safety in patients with diabetes and.
The incidence of major bleeding events increased with age and occurred at a rate of 0.9 events per 100 patient-years in patients aged 75 years.
Stroke occurred in 43 (0.7 events per 100 patient-years) patients, with SE occurring in a further 8 patients (0.1 events per 100 patient-years).Bayer invested in generating real world data for its anti coagulant Xarelto to from DECISION S QAM 1 at Indian Institute of Management Lucknow.
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.Nelson, PharmD, director of Health Economics and Outcomes at Janssen Scientific Affairs, LLC, about comparative data on.The authors thank Birgit Schmidt for Global Project Management and David Whitford for editorial assistance in the preparation of the manuscript, with funding from Bayer HealthCare Pharmaceuticals and Janssen Scientific Affairs, LLC.The incidence of major gastrointestinal bleeding was 0.9 events per 100 patient-years ( Table.
All content in NOAA View is in the public domain and is free to use as you see fit. Add Data Capture images Download files Contact Us Subscribe To Updates-.
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population.Strengths of this study include its meaningful sample size and a prospective design allowing for greater completeness of data and potentially better data quality compared with retrospective designs.A high volume of prospectively collected information in large patient groups is still lacking.The lead statistician oversaw programming and validation of the statistical analyses.All-cause death occurred in 118 patients (1.9 events per 100 patient-years) within the study treatment period, with the adjudicated cause of death due primarily to cardiovascular causes, mainly heart failure, followed by cancer ( Table.In compliance with Good Clinical Practice (GCP) standards, data management and statistical analyses were overseen by the sponsor.An independent Central Adjudication Committee (CAC) of five expert physicians (not directly involved in the care of XANTUS study patients) adjudicated major bleeding, stroke, SE, TIA, MI, and all-cause death.Barchart is a leader in financial technology, market data and trading solutions.